Navigation Links
Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:1/23/2008

esponses," said Steven W. King, president and CEO of Peregrine. "We are optimistic that this new trial, along with our other Phase II bavituximab breast cancer trial, will provide us with valuable insights into bavituximab's potential in this important disease. We are now proceeding with final preparations for the trial and look forward to study initiation in the near future."

Tumor response in this study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

The National Cancer Institute estimates that approximately 178,480 U.S. women were diagnosed with breast cancer in 2007 and 40,460 women died of the disease. According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Peregrine has now received regulatory approval for three Phase II clinical trials to study the anti-tumor effects of bavituximab in combination with chemotherapy: A breast cancer protocol in combination with docetaxel, a second breast cancer protocol in combination with carboplatin plus paclitaxel, and
'/>"/>

SOURCE Peregrine Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , August 27, 2015 According to ... (Transfer, Hammock, Toilet, Seating, Universal, Standing, Bariatric ), Material (Nylon, Padded, ... Forecast to 2020", published by MarketsandMarkets, the Medical Lifting Sling Market ... 411.5 Million in 2015, at a CAGR of 11.4 % from ... ma rket data T ables and ...
(Date:8/27/2015)... 2015   Proxsys Rx, the nation,s ... expanding its population health management services with ... care program for hospitals and health systems. ... with technology systems and pharmacy support services ... been mandated by Center for Medicare and ...
(Date:8/27/2015)... -- NorthStar Anesthesia , one of the country,s leading ... by Mercy, based in Toledo, Ohio , ... Mercy St. Vincent  Medical Center and Mercy St. Anne ... Charles  Hospital in Oregon and ... "As we looked to create a more organized ...
Breaking Medicine Technology:Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4Rx Care Management by Proxsys Rx - Transition of Care Technology Helps Prevent Hospital Medication Errors 2Four Mercy Hospitals in Northwest Ohio Select NorthStar Anesthesia 2
... an urgent need for more,comprehensive lipid control to protect ... A new 30-year analysis of the,National Health and Nutrition ... (NLA) indicates that while,Americans are doing a better job ... with high triglycerides, a blood fat linked to heart,disease, ...
... Nov. 7 Data from an investigational,open-label, ... (Epoetin alfa) in treating anemia in subjects ... (CKD) were presented today at the American ... three dosing groups, including the FDA-approved,three-times-per-week (TIW) ...
Cached Medicine Technology:New Analysis Shows Troubling Trend in Triglyceride Levels May Be Linked to Rising Rates of Obesity 2New Analysis Shows Troubling Trend in Triglyceride Levels May Be Linked to Rising Rates of Obesity 3Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 2Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 3Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 4Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 5Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 6
(Date:8/28/2015)... RESTON, Va. (PRWEB) , ... August 28, 2015 ... ... Innovation , which is dedicated to distributing health information technology innovation to transform ... industry survey. Results of the survey will be de-identified and aggregated before being ...
(Date:8/28/2015)... ... August 28, 2015 , ... United Benefit Advisors ... TJS Insurance Group as its newest Partner Firm. Founded in 1924 and headquartered ... them focused on their goals. Within the past 10 years, TJS Insurance Group ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Plaintiffs Steering Committee (PSC) ... Testosterone Replacement Therapy Products Liability Litigation, are in the midst of ongoing discussion ... PSC may receive for corporate employees involved in the production or marketing of ...
(Date:8/28/2015)... ... August 28, 2015 , ... Inc. magazine today ranked ... an exclusive ranking of the nation’s fastest-growing private companies. The list was unveiled online ... growth of 85% over the last three years, PREVENT ranks higher on the list ...
(Date:8/28/2015)... ... August 28, 2015 , ... Where can successful, well ... MillionaireMatchmakerOnline.net is set up to help quality singles find dating partners or ideal ... are rich, gorgeous, well educated, or attractive. , It updates profiles under the ...
Breaking Medicine News(10 mins):Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2Health News:MillionaireMatchmakerOnline.net Collects and Updates Newest Millionaire and Quality Single Profiles on the Page of Millionaire Matchmaker Online Canada. 2Health News:MillionaireMatchmakerOnline.net Collects and Updates Newest Millionaire and Quality Single Profiles on the Page of Millionaire Matchmaker Online Canada. 3
... FARMINGTON HILLS, Mich., Aug. 14 Work and economy related ... to a new independent survey conducted by American Laser Centers, the ... half of the respondents who took part in the survey (47 ... no stress. , , The physical ...
... NOVATO, Calif., Aug. 14 Purple Communications, Inc. (Nasdaq: ... and professional interpreting for deaf, hard of hearing, and speech impaired ... 2009. On August 13, 2009, the Company filed with the Securities ... the quarter ended June 30, 2009. , , ...
... , , , ... implementation of successful payment strategies enables the North American home ... achieve double digit growth in the traditionally mature patient monitoring ... mature market is the increasing incidence of cardiovascular disease (CD) ...
... findings published in the August issue of the Journal ... use of magnetic resonance imaging (MRI) as a means to ... Researchers found that women diagnosed with breast cancer who received ... breast conserving therapy (BCT), and may face delays in treatment. ...
... , , BELLEVUE, Wash., Aug. ... solutions, today announced the new Edifecs5010(TM) Compliance ... and services for healthcare providers, payers, health plans, ISVs, and clearinghouses ... , , Edifecs, the gold standard for HIPAA ...
... , RICHMOND, Calif., Aug. 14 ... specialty pharmaceutical company focused on the development and commercialization of ... announced financial results for the three and six months ended ... Oclassen, President and Chief Executive Officer commented, "Our recently announced ...
Cached Medicine News:Health News:Purple Communications(TM) Announces Second Quarter 2009 Results 2Health News:Purple Communications(TM) Announces Second Quarter 2009 Results 3Health News:Purple Communications(TM) Announces Second Quarter 2009 Results 4Health News:Purple Communications(TM) Announces Second Quarter 2009 Results 5Health News:Purple Communications(TM) Announces Second Quarter 2009 Results 6Health News:Purple Communications(TM) Announces Second Quarter 2009 Results 7Health News:Purple Communications(TM) Announces Second Quarter 2009 Results 8Health News:Smart Payment Strategies Enable Growth in Home Health Care and Disease Management Markets for Remote Patient Monitoring, Finds Frost & Sullivan 2Health News:Smart Payment Strategies Enable Growth in Home Health Care and Disease Management Markets for Remote Patient Monitoring, Finds Frost & Sullivan 3Health News:Smart Payment Strategies Enable Growth in Home Health Care and Disease Management Markets for Remote Patient Monitoring, Finds Frost & Sullivan 4Health News:MRI may be unnecessary prior to treatment in most newly diagnosed breast cancer patients 2Health News:Edifecs Launches the Edifecs5010(TM) Compliance Suite of Tools, Resources and Services for 5010 Migration. 2Health News:Edifecs Launches the Edifecs5010(TM) Compliance Suite of Tools, Resources and Services for 5010 Migration. 3Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 2Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 3Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 4Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 5Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 6Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 7Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 8Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 9Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 10Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 11Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 12Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 13
This high-capacity stand-on scale provides extra sensitivity and support to patients who are unsteady on their feet. Advanced technology compensates for patient movement....
... new screening, diagnostic, treatment assessment and patient ... sleep-related breathing disorders. The Watch-PAT 100 is ... an ambulatory, reliable, patient friendly diagnostic evaluation ... number of OSA sufferers, and to the ...
... synthesized by the parathyroid glands [1,2] ... extracellular calcium concentrations. PTH prevents hypocalcemia ... calcium excretion by the kidney. Following ... is rapidly degraded into 4 fragments: ...
... Dehydroepiandrosterone (DHEA) is produced in the ... the gonads [1,2,3]. DHEA serves as a ... has relatively weak androgenic activity, estimated at ... neonates, peripubertal children and in adult women, ...
Medicine Products: